Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01584284 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
A Phase 1 study, sponsored by Genelux Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01584284: Completed Phase 1 study, sponsored by Genelux Corporation.
NCT01584284 is a Phase 1 study that has completed, run by Genelux Corporation. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01584284, a Phase 1 study, has completed, sponsored by Genelux Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
Primary Outcome
Evaluation of changes in laboratory tests (hematological, chemistry), immunogenicity and physical examination
Interventions
- BIOLOGICAL GL-ONC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT01584284 record still lists
NCT01584284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which GL-ONC1 is the first listed.
NCT01584284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01584284 about?
NCT01584284 is a clinical study titled "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer". The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
What is the current status of trial NCT01584284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01584284?
The interventions under investigation include: GL-ONC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01584284?
This trial is sponsored by Genelux Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01584284's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia